The latest update is out from Monte Rosa Therapeutics ( (GLUE) ).
Monte Rosa Therapeutics has entered a global license agreement with Novartis to advance its VAV1 molecular glue degraders, including MRT-6160, aimed at treating immune-mediated conditions. This deal grants Novartis exclusive rights to develop and commercialize these compounds while Monte Rosa receives a $150 million upfront payment and potential milestone payments up to $2.1 billion. This collaboration is expected to accelerate the clinical development of MRT-6160 and expand its therapeutic applications, enhancing Monte Rosa’s financial resources and operational potential.
Find detailed analytics on GLUE stock on TipRanks’ Stock Analysis page.
